Seattle Genetics and Millennium Highlight Pivotal Data on ADCETRIS in Relapsed or Refractory Systemic ALCL at ASH Annual Meeting
Seattle Genetics, Inc. (Nasdaq: SGEN) and Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited, today reported updated data from a pivotal trial of single-agent ADCETRIS in relapsed or refractory systemic anaplastic large cell lymphoma at the 53rd American Society of Hematology Annual Meeting and Exposition being held December 10-13, 2011 in San Diego, CA. ADCETRIS is an antibody-drug conjugate directed to CD30, which is expressed in ALCL.
“This clinical trial demonstrates that durable complete remissions can be achieved with ADCETRIS in this aggressive type of T-cell lymphoma that expresses CD30,” said Dr. Ranjana Advani, Professor of Medicine/Oncology at Stanford University Medical Center. “These data reinforce the role of ADCETRIS in relapsed or refractory systemic ALCL patients, and its potential to provide an important therapeutic option for eligible patients.”
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.